Reporting bias in industry-supported medication trials presented at the American Psychiatric Association meeting.
作者信息
Sen Srijan, Prabhu Maya
出版信息
J Clin Psychopharmacol. 2012 Jun;32(3):435. doi: 10.1097/JCP.0b013e318253d737.
Abstract
摘要
相似文献
1
Reporting bias in industry-supported medication trials presented at the American Psychiatric Association meeting.在美国精神病学协会会议上发表的由行业资助的药物试验中的报告偏倚。
J Clin Psychopharmacol. 2012 Jun;32(3):435. doi: 10.1097/JCP.0b013e318253d737.
2
Drug research: marketing before evidence, sales before safety.药物研究：证据未出便进行营销，安全未证便开始销售。
Dtsch Arztebl Int. 2010 Apr;107(16):277-8. doi: 10.3238/arztebl.2010.0277. Epub 2010 Apr 23.
3
Bias in the design, interpretation, and publication of industry-sponsored clinical research.行业资助的临床研究在设计、解读和发表过程中的偏倚。
Minn Med. 2008 Jun;91(6):46-7.
4
Comments on 'The potential for bias in the reporting of industry sponsored clinical trials' by Stephen Pyke et al. and 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry sponsored clinical trials' by James Matcham et al. Pharmaceutical Statistics.对斯蒂芬·派克等人所著的《行业资助临床试验报告中的偏倚可能性》以及詹姆斯·马查姆等人所著的《制药行业资助临床试验报告与发表中统计学家的建议最佳实践》的评论。《制药统计学》
Pharm Stat. 2011 Jan-Feb;10(1):80-1. doi: 10.1002/pst.427.
5
Germany launches investigation into human trials scandal.德国对人体试验丑闻展开调查。
Lancet. 2013 Jul 13;382(9887):115-6. doi: 10.1016/s0140-6736(13)61548-2.
6
The impact of selective publication on clinical research in pain.选择性发表对疼痛临床研究的影响。
Pain. 2008 Dec;140(3):401-404. doi: 10.1016/j.pain.2008.10.026. Epub 2008 Nov 11.
7
Comparison of schizophrenia drugs often favors firm funding study.
Washington Post. 2006 Apr 12:A1, A6.
8
Correspondence (letter to the editor): Trend gives cause for concern.读者来信（致编辑的信）：趋势令人担忧。
Dtsch Arztebl Int. 2010 Sep;107(38):670-1; author reply 673-4. doi: 10.3238/arztebl.2010.0670b. Epub 2010 Sep 24.
9
Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research.代笔、数据操纵与金元外交：制药公司如何在临床研究中幕后操纵
Ann Emerg Med. 2008 Aug;52(2):137-9. doi: 10.1016/j.annemergmed.2008.06.009.
10
[ACCOMPLISH and the risks with company sponsored clinical trials].[ACCOMPLISH 与公司赞助的临床试验风险]
Lakartidningen. 2009;106(7):450.
本文引用的文献
1
Psychiatrists' relationships with pharmaceutical companies: part of the problem or part of the solution?精神科医生与制药公司的关系：问题的一部分还是解决方案的一部分？
JAMA. 2010 Mar 24;303(12):1192-3. doi: 10.1001/jama.2010.317.
2
Utilization, price, and spending trends for antidepressants in the US Medicaid Program.美国医疗补助计划中抗抑郁药的使用情况、价格及支出趋势。
Res Social Adm Pharm. 2008 Sep;4(3):244-57. doi: 10.1016/j.sapharm.2007.06.019. Epub 2008 Aug 8.
3
Selective publication of antidepressant trials and its influence on apparent efficacy.抗抑郁药物试验的选择性发表及其对表面疗效的影响。
N Engl J Med. 2008 Jan 17;358(3):252-60. doi: 10.1056/NEJMsa065779.
4
Generic fluoxetine and choice of antidepressant medication.
Psychiatr Serv. 2007 Jan;58(1):128-30. doi: 10.1176/ps.2007.58.1.128.
5
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.对于抑郁症患者，在选择性5-羟色胺再摄取抑制剂（SSRI）治疗失败后使用安非他酮缓释片、舍曲林或文拉法辛缓释片。
N Engl J Med. 2006 Mar 23;354(12):1231-42. doi: 10.1056/NEJMoa052963.
6
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.抗精神病药物对慢性精神分裂症患者的疗效。
N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.
7
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?随机药物试验中资金与结论的关联：是治疗效果还是不良事件的反映？
JAMA. 2003 Aug 20;290(7):921-8. doi: 10.1001/jama.290.7.921.
Zotero 插件